BioCryst Pharmaceuticals Strikes Strategic $700 Million Deal, Propelling Astria's HAE Pipeline and Strengthening Its Own Focus
KalVista's Game-Changing HAE Drug Gets Green Light in EU & Switzerland, Stock Set to Explode!
European Triumph: KalVista and Ionis Celebrate Key Drug Approvals Across the EU